rossannathom
2021-10-22
Dips are always a good chance to average out
Tilray Stock: 3 Reasons to Buy the Dip<blockquote>Tilray股票：逢低买入的3个理由</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":851927186,"tweetId":"851927186","gmtCreate":1634865455857,"gmtModify":1634866373650,"author":{"id":3579310238184228,"idStr":"3579310238184228","authorId":3579310238184228,"authorIdStr":"3579310238184228","name":"rossannathom","avatar":"https://static.tigerbbs.com/fee5c4cb302a57e628de9da574d73fff","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Dips are always a good chance to average out </p></body></html>","htmlText":"<html><head></head><body><p>Dips are always a good chance to average out </p></body></html>","text":"Dips are always a good chance to average out","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/851927186","repostId":1193622859,"repostType":4,"repost":{"id":"1193622859","kind":"news","pubTimestamp":1634863923,"share":"https://www.laohu8.com/m/news/1193622859?lang=zh_CN&edition=full","pubTime":"2021-10-22 08:52","market":"us","language":"en","title":"Tilray Stock: 3 Reasons to Buy the Dip<blockquote>Tilray股票：逢低买入的3个理由</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1193622859","media":"TheStreet","summary":"Tilray stock has traded substantially higher as shares of other cannabis companies also spiked. Wall","content":"<p>Tilray stock has traded substantially higher as shares of other cannabis companies also spiked. Wall Street Memes assesses whether TLRY may present a good opportunity at current levels.</p><p><blockquote>随着其他大麻公司的股价也飙升，Tilray股价大幅走高。华尔街模因评估TLRY在当前水平上是否会提供一个好机会。</blockquote></p><p> Canadian cannabis company Tilray one of the most popular stocks of its kind on Reddit, has finally showed some signs of life and caught investors’ attention. Shares traded 14% higher on October 19, despite it still being down a whopping 42% for the year. The most probable reason for bullishness is the hiring of former Bacardi executive Blair MacNeil as the company's president.</p><p><blockquote>加拿大大麻公司Tilray是Reddit上最受欢迎的同类股票之一，终于显示出一些生机，引起了投资者的关注。10月19日，该股股价上涨14%，尽管今年以来仍下跌了42%。看涨最可能的原因是聘请百加得前高管布莱尔·麦克尼尔担任公司总裁。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b0d2d448c57e40ef7549c13c7b3e0306\" tg-width=\"1240\" tg-height=\"697\" width=\"100%\" height=\"auto\"><span>Figure 1: TLRY's IPO.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：TLRY的IPO。</span></p></blockquote></p><p> TLRY has been free-falling since the early February peaks due, in part, to lack of regulatory catalysts in the cannabis space. However, Wall Street Memes sees a few good reasons to buy the stock at depressed levels.</p><p><blockquote>自2月初达到峰值以来，TLRY一直在自由落体，部分原因是大麻领域缺乏监管催化剂。然而，华尔街迷因看到了一些在低迷水平买入该股的充分理由。</blockquote></p><p> <b>#1. Reaching for global leadership</b></p><p><blockquote><b>#1.争取全球领导地位</b></blockquote></p><p> Tilray has made key acquisitions since December of last year. The biggest corporate deal was the merger with Aphria.</p><p><blockquote>自去年12月以来，Tilray进行了重大收购。最大的公司交易是与Aphria的合并。</blockquote></p><p> Since the two combined, Tilray turned into a market leader in Canada and accelerated its long-term plan of becoming the world’s leading cannabis-focused consumer company. The Tilray-Aphria merger was justified by (1) market positioning in North America, (2) a foothold in Europe, and (3) lower production costs and synergies.</p><p><blockquote>自两者合并以来，Tilray成为加拿大的市场领导者，并加速了其成为全球领先的大麻消费公司的长期计划。Tilray-Aphria合并的合理性在于(1)北美的市场定位，(2)在欧洲的立足点，以及(3)较低的生产成本和协同效应。</blockquote></p><p> A few months ago, Tilray purchased cannabis company MedMen Enterprises, which has 24 retail locations in six U.S. states. The investment was also aligned with the company’s goal of being a key global player in the cannabis space. CEO Irwin D. Simon has said:</p><p><blockquote>几个月前，Tilray收购了大麻公司MedMen Enterprises，该公司在美国六个州拥有24个零售点。这项投资也符合该公司成为大麻领域全球主要参与者的目标。首席执行官欧文·西蒙(Irwin D.Simon)表示：</blockquote></p><p> <i>“The investment we are announcing in MedMen securities, one of the most recognized brands in the $80 billion U.S. cannabis market, is a critical step towards delivering on our objective as we work to enable Tilray to lead the U.S. market when legalization allows.”</i> <b>#2. $91 billion market opportunity</b></p><p><blockquote><i>“我们宣布对MedMen securities的投资是价值800亿美元的美国大麻市场中最受认可的品牌之一，这是实现我们目标的关键一步，因为我们致力于使Tilray在合法化允许的情况下引领美国市场。”</i><b>#2.910亿美元的市场机会</b></blockquote></p><p> Third-partydatasuggests that the legal cannabis market will reach a whopping $91 billion by 2028, implying an impressive CAGR of 26%. As medical cannabis has recently become legal in many parts of the world, further legalization can be the key catalyst boosting product demand. The expected growth in the sector is also attributed to awareness about the health benefits of cannabis.</p><p><blockquote>第三方数据表明，到2028年，合法大麻市场将达到910亿美元，这意味着令人印象深刻的26%的CAGR。随着医用大麻最近在世界许多地方合法化，进一步合法化可能是提振产品需求的关键催化剂。该部门的预期增长也归因于对大麻健康益处的认识。</blockquote></p><p> Additional data suggests that the global cannabis pharmaceutical market was set to grow from $67 million in 2019 by a CAGR of 76% through 2027. Should Tilray position itself as a key player in this rapidly growing industry, investors stand to reap the benefits over the next several years.</p><p><blockquote>其他数据表明，到2027年，全球大麻药品市场将从2019年的6700万美元增长76%。如果Tilray将自己定位为这个快速增长的行业的关键参与者，投资者将在未来几年内获得好处。</blockquote></p><p> <b>#3. Good vibes from Wall Street</b></p><p><blockquote><b>#3.华尔街的良好氛围</b></blockquote></p><p> Current share price of $11.50, at last check, is still far from sell-sideconsensusof $14.73. Despite an average neutral rating among analysts, Wall Street still sees 27% upside potential over the next twelve months.</p><p><blockquote>根据上次检查，目前股价为11.50美元，距离卖方共识的14.73美元仍有很大差距。尽管分析师的平均评级为中性，但华尔街仍认为未来12个月仍有27%的上涨潜力。</blockquote></p><p> Jefferies’ analyst Owen Bennett is much more optimistic, and sees gain potential of 90% at his price target of $22. HeexpectsTilray to strike sizable deals in the US sometime soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.</p><p><blockquote>杰富瑞(Jefferies)分析师欧文·贝内特(Owen Bennett)更为乐观，他认为目标价为22美元，上涨潜力为90%。他预计斯蒂尔雷很快就会在美国达成大规模交易。该分析师还认为，Tilray应该购买大麻资产，以实现公司雄心勃勃的销售目标。</blockquote></p><p> A bit less bullish is Bank of America’s analyst Heather Balsky. Still, shebelievesin 48% upside at a price target of $15. According to the analyst, the acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe.</p><p><blockquote>美国银行分析师希瑟·巴尔斯基(Heather Balsky)则不那么乐观。尽管如此，她仍相信上涨48%，目标价为15美元。该分析师表示，收购MedMen使该公司在美国处于有利地位，并在加拿大和欧洲提供了分销机会。</blockquote></p><p> Even the skeptical ones, including Piper Sandler analyst Michael Lavery, has a price target of $14. At those levels, TLRY would be worth 38% more than it is now. The analyst’s caution is based on increased competition from low-price providers.</p><p><blockquote>即使是持怀疑态度的人，包括Piper Sandler分析师Michael Lavery，也将目标价定为14美元。按照这些水平，TLRY的价值将比现在高出38%。分析师的谨慎是基于来自低价供应商的竞争加剧。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: 3 Reasons to Buy the Dip<blockquote>Tilray股票：逢低买入的3个理由</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: 3 Reasons to Buy the Dip<blockquote>Tilray股票：逢低买入的3个理由</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-10-22 08:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Tilray stock has traded substantially higher as shares of other cannabis companies also spiked. Wall Street Memes assesses whether TLRY may present a good opportunity at current levels.</p><p><blockquote>随着其他大麻公司的股价也飙升，Tilray股价大幅走高。华尔街模因评估TLRY在当前水平上是否会提供一个好机会。</blockquote></p><p> Canadian cannabis company Tilray one of the most popular stocks of its kind on Reddit, has finally showed some signs of life and caught investors’ attention. Shares traded 14% higher on October 19, despite it still being down a whopping 42% for the year. The most probable reason for bullishness is the hiring of former Bacardi executive Blair MacNeil as the company's president.</p><p><blockquote>加拿大大麻公司Tilray是Reddit上最受欢迎的同类股票之一，终于显示出一些生机，引起了投资者的关注。10月19日，该股股价上涨14%，尽管今年以来仍下跌了42%。看涨最可能的原因是聘请百加得前高管布莱尔·麦克尼尔担任公司总裁。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b0d2d448c57e40ef7549c13c7b3e0306\" tg-width=\"1240\" tg-height=\"697\" width=\"100%\" height=\"auto\"><span>Figure 1: TLRY's IPO.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：TLRY的IPO。</span></p></blockquote></p><p> TLRY has been free-falling since the early February peaks due, in part, to lack of regulatory catalysts in the cannabis space. However, Wall Street Memes sees a few good reasons to buy the stock at depressed levels.</p><p><blockquote>自2月初达到峰值以来，TLRY一直在自由落体，部分原因是大麻领域缺乏监管催化剂。然而，华尔街迷因看到了一些在低迷水平买入该股的充分理由。</blockquote></p><p> <b>#1. Reaching for global leadership</b></p><p><blockquote><b>#1.争取全球领导地位</b></blockquote></p><p> Tilray has made key acquisitions since December of last year. The biggest corporate deal was the merger with Aphria.</p><p><blockquote>自去年12月以来，Tilray进行了重大收购。最大的公司交易是与Aphria的合并。</blockquote></p><p> Since the two combined, Tilray turned into a market leader in Canada and accelerated its long-term plan of becoming the world’s leading cannabis-focused consumer company. The Tilray-Aphria merger was justified by (1) market positioning in North America, (2) a foothold in Europe, and (3) lower production costs and synergies.</p><p><blockquote>自两者合并以来，Tilray成为加拿大的市场领导者，并加速了其成为全球领先的大麻消费公司的长期计划。Tilray-Aphria合并的合理性在于(1)北美的市场定位，(2)在欧洲的立足点，以及(3)较低的生产成本和协同效应。</blockquote></p><p> A few months ago, Tilray purchased cannabis company MedMen Enterprises, which has 24 retail locations in six U.S. states. The investment was also aligned with the company’s goal of being a key global player in the cannabis space. CEO Irwin D. Simon has said:</p><p><blockquote>几个月前，Tilray收购了大麻公司MedMen Enterprises，该公司在美国六个州拥有24个零售点。这项投资也符合该公司成为大麻领域全球主要参与者的目标。首席执行官欧文·西蒙(Irwin D.Simon)表示：</blockquote></p><p> <i>“The investment we are announcing in MedMen securities, one of the most recognized brands in the $80 billion U.S. cannabis market, is a critical step towards delivering on our objective as we work to enable Tilray to lead the U.S. market when legalization allows.”</i> <b>#2. $91 billion market opportunity</b></p><p><blockquote><i>“我们宣布对MedMen securities的投资是价值800亿美元的美国大麻市场中最受认可的品牌之一，这是实现我们目标的关键一步，因为我们致力于使Tilray在合法化允许的情况下引领美国市场。”</i><b>#2.910亿美元的市场机会</b></blockquote></p><p> Third-partydatasuggests that the legal cannabis market will reach a whopping $91 billion by 2028, implying an impressive CAGR of 26%. As medical cannabis has recently become legal in many parts of the world, further legalization can be the key catalyst boosting product demand. The expected growth in the sector is also attributed to awareness about the health benefits of cannabis.</p><p><blockquote>第三方数据表明，到2028年，合法大麻市场将达到910亿美元，这意味着令人印象深刻的26%的CAGR。随着医用大麻最近在世界许多地方合法化，进一步合法化可能是提振产品需求的关键催化剂。该部门的预期增长也归因于对大麻健康益处的认识。</blockquote></p><p> Additional data suggests that the global cannabis pharmaceutical market was set to grow from $67 million in 2019 by a CAGR of 76% through 2027. Should Tilray position itself as a key player in this rapidly growing industry, investors stand to reap the benefits over the next several years.</p><p><blockquote>其他数据表明，到2027年，全球大麻药品市场将从2019年的6700万美元增长76%。如果Tilray将自己定位为这个快速增长的行业的关键参与者，投资者将在未来几年内获得好处。</blockquote></p><p> <b>#3. Good vibes from Wall Street</b></p><p><blockquote><b>#3.华尔街的良好氛围</b></blockquote></p><p> Current share price of $11.50, at last check, is still far from sell-sideconsensusof $14.73. Despite an average neutral rating among analysts, Wall Street still sees 27% upside potential over the next twelve months.</p><p><blockquote>根据上次检查，目前股价为11.50美元，距离卖方共识的14.73美元仍有很大差距。尽管分析师的平均评级为中性，但华尔街仍认为未来12个月仍有27%的上涨潜力。</blockquote></p><p> Jefferies’ analyst Owen Bennett is much more optimistic, and sees gain potential of 90% at his price target of $22. HeexpectsTilray to strike sizable deals in the US sometime soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.</p><p><blockquote>杰富瑞(Jefferies)分析师欧文·贝内特(Owen Bennett)更为乐观，他认为目标价为22美元，上涨潜力为90%。他预计斯蒂尔雷很快就会在美国达成大规模交易。该分析师还认为，Tilray应该购买大麻资产，以实现公司雄心勃勃的销售目标。</blockquote></p><p> A bit less bullish is Bank of America’s analyst Heather Balsky. Still, shebelievesin 48% upside at a price target of $15. According to the analyst, the acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe.</p><p><blockquote>美国银行分析师希瑟·巴尔斯基(Heather Balsky)则不那么乐观。尽管如此，她仍相信上涨48%，目标价为15美元。该分析师表示，收购MedMen使该公司在美国处于有利地位，并在加拿大和欧洲提供了分销机会。</blockquote></p><p> Even the skeptical ones, including Piper Sandler analyst Michael Lavery, has a price target of $14. At those levels, TLRY would be worth 38% more than it is now. The analyst’s caution is based on increased competition from low-price providers.</p><p><blockquote>即使是持怀疑态度的人，包括Piper Sandler分析师Michael Lavery，也将目标价定为14美元。按照这些水平，TLRY的价值将比现在高出38%。分析师的谨慎是基于来自低价供应商的竞争加剧。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/memestocks/other-memes/3-reasons-to-buy-tilray-stock-now\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/3-reasons-to-buy-tilray-stock-now","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193622859","content_text":"Tilray stock has traded substantially higher as shares of other cannabis companies also spiked. Wall Street Memes assesses whether TLRY may present a good opportunity at current levels.\nCanadian cannabis company Tilray one of the most popular stocks of its kind on Reddit, has finally showed some signs of life and caught investors’ attention. Shares traded 14% higher on October 19, despite it still being down a whopping 42% for the year. The most probable reason for bullishness is the hiring of former Bacardi executive Blair MacNeil as the company's president.\nFigure 1: TLRY's IPO.\nTLRY has been free-falling since the early February peaks due, in part, to lack of regulatory catalysts in the cannabis space. However, Wall Street Memes sees a few good reasons to buy the stock at depressed levels.\n#1. Reaching for global leadership\nTilray has made key acquisitions since December of last year. The biggest corporate deal was the merger with Aphria.\nSince the two combined, Tilray turned into a market leader in Canada and accelerated its long-term plan of becoming the world’s leading cannabis-focused consumer company. The Tilray-Aphria merger was justified by (1) market positioning in North America, (2) a foothold in Europe, and (3) lower production costs and synergies.\nA few months ago, Tilray purchased cannabis company MedMen Enterprises, which has 24 retail locations in six U.S. states. The investment was also aligned with the company’s goal of being a key global player in the cannabis space. CEO Irwin D. Simon has said:\n\n“The investment we are announcing in MedMen securities, one of the most recognized brands in the $80 billion U.S. cannabis market, is a critical step towards delivering on our objective as we work to enable Tilray to lead the U.S. market when legalization allows.”\n\n#2. $91 billion market opportunity\nThird-partydatasuggests that the legal cannabis market will reach a whopping $91 billion by 2028, implying an impressive CAGR of 26%. As medical cannabis has recently become legal in many parts of the world, further legalization can be the key catalyst boosting product demand. The expected growth in the sector is also attributed to awareness about the health benefits of cannabis.\nAdditional data suggests that the global cannabis pharmaceutical market was set to grow from $67 million in 2019 by a CAGR of 76% through 2027. Should Tilray position itself as a key player in this rapidly growing industry, investors stand to reap the benefits over the next several years.\n#3. Good vibes from Wall Street\nCurrent share price of $11.50, at last check, is still far from sell-sideconsensusof $14.73. Despite an average neutral rating among analysts, Wall Street still sees 27% upside potential over the next twelve months.\nJefferies’ analyst Owen Bennett is much more optimistic, and sees gain potential of 90% at his price target of $22. HeexpectsTilray to strike sizable deals in the US sometime soon. The analyst also thinks that Tilray should buy cannabis assets to achieve the company’s ambitious sales target.\nA bit less bullish is Bank of America’s analyst Heather Balsky. Still, shebelievesin 48% upside at a price target of $15. According to the analyst, the acquisition of MedMen positions the company well in the US and provides distribution opportunities in Canada and Europe.\nEven the skeptical ones, including Piper Sandler analyst Michael Lavery, has a price target of $14. At those levels, TLRY would be worth 38% more than it is now. The analyst’s caution is based on increased competition from low-price providers.","news_type":1,"symbols_score_info":{"TLRY":0.9}},"isVote":1,"tweetType":1,"viewCount":2847,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/851927186"}
精彩评论